Boston Scientific Corporation
BSX
$100.56
$1.641.66%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 566.00M | 469.00M | 325.00M | 494.00M | 505.00M |
| Total Depreciation and Amortization | 348.00M | 306.00M | 311.00M | 304.00M | 313.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 218.00M | 61.00M | 386.00M | 109.00M | 196.00M |
| Change in Net Operating Assets | 324.00M | 166.00M | -209.00M | -743.00M | -57.00M |
| Cash from Operations | 1.46B | 1.00B | 813.00M | 164.00M | 957.00M |
| Capital Expenditure | -277.00M | -179.00M | -155.00M | -179.00M | -267.00M |
| Sale of Property, Plant, and Equipment | 2.00M | 0.00 | 0.00 | 1.00M | 0.00 |
| Cash Acquisitions | -3.42B | -1.13B | -48.00M | -47.00M | -793.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -11.00M | -121.00M | -68.00M | -60.00M | 7.00M |
| Cash from Investing | -3.70B | -1.43B | -271.00M | -285.00M | -1.05B |
| Total Debt Issued | 189.00M | 22.00M | 0.00 | 2.15B | -- |
| Total Debt Repaid | 0.00 | 0.00 | 0.00 | -529.00M | 0.00 |
| Issuance of Common Stock | 28.00M | 96.00M | 26.00M | 80.00M | 17.00M |
| Repurchase of Common Stock | -87.00M | -- | -- | -- | -56.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | 0.00 |
| Other Financing Activities | 84.00M | -111.00M | -2.00M | -127.00M | 54.00M |
| Cash from Financing | 214.00M | 7.00M | 24.00M | 1.57B | 15.00M |
| Foreign Exchange rate Adjustments | -9.00M | 6.00M | -1.00M | -7.00M | 4.00M |
| Miscellaneous Cash Flow Adjustments | -1.00M | -- | -- | -- | -- |
| Net Change in Cash | -2.04B | -412.00M | 565.00M | 1.44B | -77.00M |